A Dutch court has ruled in favor of Halozyme Therapeutics in a high-stakes patent dispute with Merck, blocking the sale of Merck's subcutaneous formulation of Keytruda (pembrolizumab) across several European countries. The ruling marks a significant victory for Halozyme's proprietary ENHANZE drug delivery platform and sends a clear signal to the global biologics manufacturing industry: subcutaneous formulation technology is both a competitive differentiator and a legally contested frontier.

The case centers on Halozyme's recombinant human hyaluronidase enzyme (rHuPH20), the active component of its ENHANZE platform. This enzyme temporarily degrades hyaluronan in the subcutaneous tissue, creating a space that allows large-volume biologics to be delivered via injection rather than intravenous infusion. Merck sought to use a similar approach to convert its blockbuster intravenous Keytruda into a subcutaneous version, which would offer significant convenience advantages for oncology patients and healthcare systems. Halozyme argued that Merck's formulation infringed on its patent portfolio covering the rHuPH20 technology and its applications in biologics delivery.

For contract development and manufacturing organizations (CDMOs) and API suppliers, the ruling carries immediate strategic implications. Subcutaneous biologics formulations represent one of the fastest-growing segments in the pharmaceutical industry, driven by patient preference for at-home administration, reduced hospital chair time, and lower healthcare infrastructure costs. The global subcutaneous biologics market is projected to exceed $150 billion by 2030, with oncology, immunology, and rare disease therapies leading adoption. Halozyme's patent victory reinforces that any manufacturer seeking to develop subcutaneous versions of existing IV biologics must either license the ENHANZE platform or develop alternative hyaluronidase-based delivery systems that do not infringe on Halozyme's intellectual property.

Halozyme has already licensed its ENHANZE technology to more than a dozen pharmaceutical companies, including Roche, Pfizer, Janssen, AbbVie, and Eli Lilly. These partnerships generate substantial royalty revenues for Halozyme and create a de facto standard for subcutaneous biologics formulation. The Dutch court's ruling strengthens Halozyme's negotiating position in future licensing discussions and may prompt additional pharmaceutical companies to secure ENHANZE licenses rather than risk costly patent litigation. For CDMOs specializing in biologics fill-finish and formulation development, this means that familiarity with the ENHANZE platform and rHuPH20 handling will become an increasingly valuable capability.

The manufacturing challenges associated with subcutaneous biologics are non-trivial. Unlike intravenous formulations, which can be delivered in large volumes over extended infusion periods, subcutaneous formulations must concentrate the drug substance into a small injection volume—typically 1 to 5 milliliters. This requires sophisticated formulation science to maintain protein stability at high concentrations, prevent aggregation, and ensure consistent pharmacokinetic profiles. The addition of rHuPH20 introduces additional complexity, as the enzyme must be manufactured to pharmaceutical grade, stored under controlled conditions, and co-formulated or co-administered with the biologic drug substance.

For API and intermediate suppliers, the ruling underscores the growing importance of enzyme manufacturing capabilities. Recombinant hyaluronidase is produced using mammalian cell culture systems, requiring specialized bioreactor capacity, purification infrastructure, and quality control systems. As more pharmaceutical companies pursue subcutaneous formulations under ENHANZE licenses, demand for high-purity rHuPH20 and related enzyme intermediates is expected to increase substantially. Suppliers with established capabilities in recombinant enzyme production, aseptic processing, and cold-chain logistics will be well-positioned to capture this growing market segment.

The European patent ruling also has implications for the broader competitive landscape. Several companies are developing alternative approaches to subcutaneous biologics delivery, including novel hyaluronidase enzymes, hyaluronidase-free formulation technologies, and needle-free injection systems. The strength of Halozyme's patent position, as affirmed by the Dutch court, may accelerate investment in these alternative approaches as companies seek to avoid licensing dependencies. This could create new opportunities for CDMOs and technology providers that offer differentiated formulation and delivery solutions.

Merck has not yet announced whether it will appeal the Dutch ruling, and parallel patent proceedings in other jurisdictions remain pending. However, the European decision is likely to influence the global trajectory of subcutaneous Keytruda development. Keytruda generated approximately $25 billion in global sales in 2025, making it the world's best-selling drug. A subcutaneous version would extend the product's lifecycle and competitive position, particularly as biosimilar competition for the intravenous formulation approaches. The patent dispute highlights the strategic value that formulation technology holds in the modern pharmaceutical industry, where drug delivery innovation can be as commercially significant as the active pharmaceutical ingredient itself.

For the pharmaceutical supply chain, the Halozyme-Merck ruling reinforces a broader trend: the increasing importance of enabling technologies and platform intellectual property in biologics manufacturing. As the industry shifts toward more convenient, patient-friendly drug delivery formats, CDMOs and suppliers that invest in subcutaneous formulation expertise, enzyme manufacturing, and related capabilities will be positioned to serve a rapidly expanding market. Companies that ignore this trend risk being excluded from some of the most valuable biologics development programs of the coming decade.